AU1102401A - Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products - Google Patents

Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products

Info

Publication number
AU1102401A
AU1102401A AU11024/01A AU1102401A AU1102401A AU 1102401 A AU1102401 A AU 1102401A AU 11024/01 A AU11024/01 A AU 11024/01A AU 1102401 A AU1102401 A AU 1102401A AU 1102401 A AU1102401 A AU 1102401A
Authority
AU
Australia
Prior art keywords
antigen
cancers
express
reducing
effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11024/01A
Inventor
Carlos F. Barbas Iii
Lloyd J. Old
Christoph Rader
Gerd Ritter
Sydney Welt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Scripps Research Institute
Memorial Sloan Kettering Cancer Center
Original Assignee
Ludwig Institute for Cancer Research Ltd
Sloan Kettering Institute for Cancer Research
Ludwig Institute for Cancer Research New York
Scripps Research Institute
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/425,638 external-priority patent/US6342587B1/en
Priority claimed from US09/543,004 external-priority patent/US6346249B1/en
Application filed by Ludwig Institute for Cancer Research Ltd, Sloan Kettering Institute for Cancer Research, Ludwig Institute for Cancer Research New York, Scripps Research Institute, Memorial Sloan Kettering Cancer Center filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU1102401A publication Critical patent/AU1102401A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
AU11024/01A 1999-10-22 2000-10-20 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products Abandoned AU1102401A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09425638 1999-10-22
US09/425,638 US6342587B1 (en) 1999-10-22 1999-10-22 A33 antigen specific immunoglobulin products and uses thereof
US09543004 2000-04-04
US09/543,004 US6346249B1 (en) 1999-10-22 2000-04-04 Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
PCT/US2000/029289 WO2001030393A2 (en) 1999-10-22 2000-10-20 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products

Publications (1)

Publication Number Publication Date
AU1102401A true AU1102401A (en) 2001-05-08

Family

ID=27026757

Family Applications (2)

Application Number Title Priority Date Filing Date
AU11024/01A Abandoned AU1102401A (en) 1999-10-22 2000-10-20 Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
AU10973/01A Abandoned AU1097301A (en) 1999-10-22 2000-10-20 Humanization of non-human, mammalian antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU10973/01A Abandoned AU1097301A (en) 1999-10-22 2000-10-20 Humanization of non-human, mammalian antibodies

Country Status (4)

Country Link
EP (1) EP1233790A2 (en)
JP (1) JP2003527334A (en)
AU (2) AU1102401A (en)
WO (1) WO2001030393A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
US6652853B2 (en) * 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents
US20030040027A1 (en) * 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
EP2145954A1 (en) 2004-09-06 2010-01-20 Kyowa Hakko Kirin Co., Ltd. Anti-A33 antibody
JP5791895B2 (en) * 2007-05-04 2015-10-07 テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー Genetically engineered rabbit antibody variable domains and uses thereof
EP2162469A4 (en) * 2007-05-21 2012-08-01 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
CA3020290A1 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
KR101882352B1 (en) * 2008-06-25 2018-07-26 에스바테크 - 어 노바티스 컴파니 엘엘씨 Humanization of rabbit antibodies using a universal antibody framework
EP2861617A1 (en) * 2012-06-15 2015-04-22 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
EP3876990A4 (en) * 2018-11-07 2023-09-06 Merck Sharp & Dohme LLC Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN110540591A (en) * 2019-08-09 2019-12-06 无锡傲锐东源生物科技有限公司 anti-Glycoprotein A33 (glycoprotin A33) monoclonal antibody and immunodetection application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190640B1 (en) * 1985-04-19 2001-02-20 Ludwig Institute For Cancer Research Method for treating neoplasia using humanized antibodies which bind to antigen A33
AU675268B2 (en) * 1992-12-10 1997-01-30 Celltech Limited Humanised antibodies directed against A33 antigen
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
US6652853B2 (en) * 2001-03-08 2003-11-25 Ludwig Institute For Cancer Research Method for treating cancer using A33 specific antibodies and chemotherapeutic agents

Also Published As

Publication number Publication date
AU1097301A (en) 2001-05-08
WO2001030393A2 (en) 2001-05-03
JP2003527334A (en) 2003-09-16
EP1233790A2 (en) 2002-08-28
WO2001030393A8 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
AU1462300A (en) Human pan-hcv human monoclonal antibodies
AU4314900A (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
AU1290001A (en) Antibodies
ZA964614B (en) Methods for the preparation of substantially monomeric callcheamicin derivative carrier conjugates.
AU4992997A (en) Humanized anti-cd11a antibodies
ZA968957B (en) Process for the preparation of dihaloazolopyrimidines.
AU3546400A (en) Tandem immuno-assay for cancer
IL121437A0 (en) Process for the preparation of nootkatone
AU5686698A (en) Methods for the production of chicken monoclonal antibodies
AU1102401A (en) Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
AU7287598A (en) Process for the conversion of hydrocarbons
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
AU5441000A (en) Human monoclonal antibody
AU4859200A (en) Process for enhancing the value of hydrocarbonaceous natural resources
AU7363000A (en) Method for reducing the risk of cancer
AU6542898A (en) Sialyl lewis antigens as targets for immunotherapy
AU1615701A (en) Compositions and methods for regulating tumor-associated antigen expression
AU7129796A (en) Apparatus For The Dosed, Air-Ttransported Distribution Of Substances
AU3283500A (en) Tumor-associated antigen
AU7572198A (en) Tumor-associated antigen
AU6596400A (en) Apparatus for producing radioisotope
AU7059296A (en) NK-1 receptor antagonists for the treatment of cancer
AU7096496A (en) Process for the preparation of 4-methylenepiperidines
AU5486396A (en) Process for the preparation of spiroindolines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase